Empagliflozin/metformin fixed-dose combination: a review in patients with type 2 diabetes

被引：10
作者：
Hu, Jingbo [1 ]
Zou, Ping [2 ]
Zhang, Shuo [1 ]
Zhou, Minzhi [1 ]
Tan, Xueying [3 ]
机构：
[1] Zhejiang Univ, Coll Pharmaceut Sci, Hangzhou, Zhejiang, Peoples R China
[2] Huazhong Univ Sci & Technol, Tongji Med Coll, Cent Hosp Wuhan, Dept Pharm, Wuhan, Peoples R China
[3] Ningbo Univ, Affiliated Yangming Hosp, Dept Endocrinol, Yuyao 315400, Zhejiang, Peoples R China
来源：
EXPERT OPINION ON PHARMACOTHERAPY | 2016年 / 17卷 / 18期
关键词：
Empagliflozin; metformin; sodium glucose co-transporter 2; fixed-dose tablet; COTRANSPORTER; 2; INHIBITORS; ADD-ON; CARDIOVASCULAR OUTCOMES; DOUBLE-BLIND; SGLT2; INHIBITOR; METFORMIN; GLUCOSE; SAFETY; PHARMACOKINETICS; METAANALYSIS;
D O I：
10.1080/14656566.2016.1258062
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Introduction: Most patients with type 2 diabetes, who receive monotherapy, are unable to maintain glucose levels with the progress of disease. Therefore, combination therapy with two or more antidiabetic agents of different classes is highly desired. Sodium glucose co-transporter 2 (SGLT2) inhibitors improve glycemic control through increasing urinary glucose excretion, which is independent of beta-cell function. In addition, they are generally well tolerated and associated with a low risk of hypoglycaemia. SGLT2 inhibitors as add-on therapy to metformin have an additive effect on glycemic control in patients with type 2 diabetes, and fixed-dose tablet is likely to reduce pill burden and then improve patients' adherence. Areas covered: This article reviews empagliflozin/metformin combination therapy for the treatment of type 2 diabetes. The clinical efficacy and tolerability of empagliflozin/metformin in patients with type 2 diabetes are discussed based on the available literature. Expert opinion: It was found that empagliflozin/metformin combination therapy could significantly improve glycemic control, body weight and blood pressure with a low risk of hypoglycaemia. In addition, the empagliflozin/metformin fixed-dose tablets, supported by bioequivalence studies, could reduce pill burden to further achieve the improved patients' adherence, better glycemic control and optimized cost-effectiveness.
引用
收藏
页码：2471 / 2477
页数：7
相关论文
共 46 条
[21]   Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus [J].
Kovacs, Christopher S. ;
Seshiah, Veeraswamy ;
Merker, Ludwig ;
Christiansen, Anita Vedel ;
Roux, Flavien ;
Salsali, Afshin ;
Kim, Gabriel ;
Stella, Peter ;
Woerle, Hans-Juergen ;
Broedl, Uli C. .
CLINICAL THERAPEUTICS, 2015, 37 (08) :1773-1788
[22]   The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus [J].
Lajara, Rosemarie .
EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (17) :2565-2585
[23]  
Launay-Mignot P, 2002, ANN ENDOCRINOL-PARIS, V63, P476
[24]   Triple therapy combinations for the treatment of type 2 diabetes - A network meta-analysis [J].
Lee, Crystal Man Ying ;
Woodward, Mark ;
Colagiuri, Stephen .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 116 :149-158
[25]   Empagliflozin as add-on to metformin in people with Type 2 diabetes [J].
Merker, L. ;
Haering, H-U. ;
Christiansen, A. V. ;
Roux, F. ;
Salsali, A. ;
Kim, G. ;
Meinicke, T. ;
Woerle, H. J. ;
Broedl, U. C. .
DIABETIC MEDICINE, 2015, 32 (12) :1555-1567
[26]   Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials [J].
Monami, M. ;
Genovese, S. ;
Mannucci, E. .
DIABETES OBESITY & METABOLISM, 2013, 15 (10) :938-953
[27]   Metformin: diamonds are forever [J].
Papanas, N. ;
Maltezos, E. ;
Mikhailidis, D. P. .
EXPERT OPINION ON PHARMACOTHERAPY, 2009, 10 (15) :2395-2397
[28]   Sodium- Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open- Label Proof- ofConcept Trial [J].
Perkins, Bruce A. ;
Cherney, David Z. I. ;
Partridge, Helen ;
Soleymanlou, Nima ;
Tschirhart, Holly ;
Zinman, Bernard ;
Fagan, Nora M. ;
Kaspers, Stefan ;
Woerle, Hans-Juergen ;
Broedl, Uli C. ;
Johansen, Odd-Erik .
DIABETES CARE, 2014, 37 (05) :1480-1483
[29]   Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition [J].
Peters, Anne L. ;
Buschur, Elizabeth O. ;
Buse, John B. ;
Cohan, Pejman ;
Diner, Jamie C. ;
Hirsch, Irl B. .
DIABETES CARE, 2015, 38 (09) :1687-1693
[30]   Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials [J].
Ray, Kausik K. ;
Seshasai, Sreenivasa Rao Kondapally ;
Wijesuriya, Shanelle ;
Sivakumaran, Rupa ;
Nethercott, Sarah ;
Preiss, David ;
Erqou, Sebhat ;
Sattar, Naveed .
LANCET, 2009, 373 (9677) :1765-1772
12345